3.76 USD
-0.06 (-1.57%)
3.78 USD
+0.02 (+0.53%)
VYGR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. VYGR has a great financial health rating, but its profitability evaluates not so good. VYGR does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- In the past year VYGR has reported negative net income.
- In the past year VYGR has reported a negative cash flow from operations.
- In multiple years VYGR reported negative net income over the last 5 years.
- In the past 5 years VYGR reported 4 times negative operating cash flow.
1.2 Ratios
- VYGR has a Return On Assets (-43.75%) which is comparable to the rest of the industry.
- VYGR has a Return On Equity of -57.27%. This is in the better half of the industry: VYGR outperforms 63.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -43.75% | ||
| ROE | -57.27% | ||
| ROIC | N/A |
ROA(3y)-2.68%
ROA(5y)-6.15%
ROE(3y)-14.79%
ROE(5y)-19.09%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for VYGR so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- VYGR does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, VYGR has more shares outstanding
- VYGR has more shares outstanding than it did 5 years ago.
- VYGR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- Based on the Altman-Z score of -0.92, we must say that VYGR is in the distress zone and has some risk of bankruptcy.
- VYGR has a Altman-Z score of -0.92. This is comparable to the rest of the industry: VYGR outperforms 56.98% of its industry peers.
- There is no outstanding debt for VYGR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.92 |
ROIC/WACCN/A
WACC8.88%
2.3 Liquidity
- VYGR has a Current Ratio of 6.29. This indicates that VYGR is financially healthy and has no problem in meeting its short term obligations.
- With a decent Current ratio value of 6.29, VYGR is doing good in the industry, outperforming 64.53% of the companies in the same industry.
- A Quick Ratio of 6.29 indicates that VYGR has no problem at all paying its short term obligations.
- The Quick ratio of VYGR (6.29) is better than 65.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.29 | ||
| Quick Ratio | 6.29 |
3. Growth
3.1 Past
- VYGR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -404.23%.
- The Revenue for VYGR has decreased by -80.88% in the past year. This is quite bad
- The Revenue has been decreasing by -5.18% on average over the past years.
EPS 1Y (TTM)-404.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-193.75%
Revenue 1Y (TTM)-80.88%
Revenue growth 3Y28.85%
Revenue growth 5Y-5.18%
Sales Q2Q%-45.73%
3.2 Future
- The Earnings Per Share is expected to decrease by -6.88% on average over the next years.
- Based on estimates for the next years, VYGR will show a decrease in Revenue. The Revenue will decrease by -8.25% on average per year.
EPS Next Y-88.71%
EPS Next 2Y-20.23%
EPS Next 3Y-9.8%
EPS Next 5Y-6.88%
Revenue Next Year-60.65%
Revenue Next 2Y-17.78%
Revenue Next 3Y-6.68%
Revenue Next 5Y-8.25%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for VYGR. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VYGR. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A cheap valuation may be justified as VYGR's earnings are expected to decrease with -9.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.23%
EPS Next 3Y-9.8%
5. Dividend
5.1 Amount
- No dividends for VYGR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
3.76
-0.06 (-1.57%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10/bmo
Earnings (Next)03-09 2026-03-09/amc
Inst Owners55.09%
Inst Owner Change-0.03%
Ins Owners0.88%
Ins Owner Change-0.21%
Market Cap209.06M
Revenue(TTM)31.32M
Net Income(TTM)-126.00M
Analysts87.78
Price Target15.3 (306.91%)
Short Float %7.31%
Short Ratio7.14
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.56%
Min EPS beat(2)-6.33%
Max EPS beat(2)11.46%
EPS beat(4)1
Avg EPS beat(4)-17.11%
Min EPS beat(4)-57.86%
Max EPS beat(4)11.46%
EPS beat(8)5
Avg EPS beat(8)79.25%
EPS beat(12)8
Avg EPS beat(12)75.9%
EPS beat(16)10
Avg EPS beat(16)73.9%
Revenue beat(2)1
Avg Revenue beat(2)9.1%
Min Revenue beat(2)-48.55%
Max Revenue beat(2)66.75%
Revenue beat(4)1
Avg Revenue beat(4)-24.46%
Min Revenue beat(4)-62.87%
Max Revenue beat(4)66.75%
Revenue beat(8)5
Avg Revenue beat(8)80.35%
Revenue beat(12)8
Avg Revenue beat(12)85.04%
Revenue beat(16)10
Avg Revenue beat(16)78%
PT rev (1m)0%
PT rev (3m)-4.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.41%
EPS NY rev (1m)0%
EPS NY rev (3m)1.13%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.44%
Revenue NY rev (1m)0%
Revenue NY rev (3m)18.12%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 6.68 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.95 | ||
| P/tB | 0.95 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.16
EYN/A
EPS(NY)-1.63
Fwd EYN/A
FCF(TTM)-2.13
FCFYN/A
OCF(TTM)-2.09
OCFYN/A
SpS0.56
BVpS3.96
TBVpS3.96
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -43.75% | ||
| ROE | -57.27% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-2.68%
ROA(5y)-6.15%
ROE(3y)-14.79%
ROE(5y)-19.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.11
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 52.74% | ||
| Cap/Sales | 6.77% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.29 | ||
| Quick Ratio | 6.29 | ||
| Altman-Z | -0.92 |
F-Score2
WACC8.88%
ROIC/WACCN/A
Cap/Depr(3y)62.69%
Cap/Depr(5y)107.19%
Cap/Sales(3y)3.93%
Cap/Sales(5y)4.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-404.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-193.75%
EPS Next Y-88.71%
EPS Next 2Y-20.23%
EPS Next 3Y-9.8%
EPS Next 5Y-6.88%
Revenue 1Y (TTM)-80.88%
Revenue growth 3Y28.85%
Revenue growth 5Y-5.18%
Sales Q2Q%-45.73%
Revenue Next Year-60.65%
Revenue Next 2Y-17.78%
Revenue Next 3Y-6.68%
Revenue Next 5Y-8.25%
EBIT growth 1Y-1309.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-78.78%
EBIT Next 3Y-14.55%
EBIT Next 5Y-12.11%
FCF growth 1Y-237.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-229.85%
OCF growth 3YN/A
OCF growth 5YN/A
VOYAGER THERAPEUTICS INC / VYGR FAQ
What is the fundamental rating for VYGR stock?
ChartMill assigns a fundamental rating of 2 / 10 to VYGR.
What is the valuation status of VOYAGER THERAPEUTICS INC (VYGR) stock?
ChartMill assigns a valuation rating of 0 / 10 to VOYAGER THERAPEUTICS INC (VYGR). This can be considered as Overvalued.
What is the profitability of VYGR stock?
VOYAGER THERAPEUTICS INC (VYGR) has a profitability rating of 1 / 10.
Can you provide the financial health for VYGR stock?
The financial health rating of VOYAGER THERAPEUTICS INC (VYGR) is 7 / 10.
Can you provide the expected EPS growth for VYGR stock?
The Earnings per Share (EPS) of VOYAGER THERAPEUTICS INC (VYGR) is expected to decline by -88.71% in the next year.